Cencora (COR)

Cencora (renamed from AmerisourceBergen in August 2023) is no longer just a drug distributor. Its core business is still large-scale pharmaceutical logistics and distribution — one of the US 'Big Three' alongside McKesson (MCK) and Cardinal Health (CAH) — but Cencora is aggressively pivoting toward higher-margin specialty pharma services: oncology, retina/ophthalmology, and physician-practice management (MSO).

The short version: Cencora is recycling capital. It is exiting non-core animal health while going deeper into human specialty MSOs. This is not routine bolt-on M&A — it is a clear strategic pivot.

Segment Breakdown

Notice the pattern: the largest segment (U.S. Healthcare Solutions) is decelerating — from a 4-6% full-year guide down to just 2.9% in Q2, prompting a 'revenue miss' narrative in management's slides. Meanwhile the International segment is running hot at +13%, well ahead of its own guidance. That divergence is exactly what investors should be watching — which piece of the business ends up carrying Cencora's growth story going forward.

Key Corporate Actions (The Specialty Pivot)

• RCA (Retina Consultants of America) — closed January 2, 2025, Cencora acquired ~85% for USD4.4 billion cash, funded via new debt. This was Cencora's entry into the retina/ophthalmology MSO space.
• OneOncology — definitive agreement signed December 15, 2025 to acquire the remaining majority equity from TPG, completed in 2026. This deepens Cencora's push into oncology MSO.
• EyeSouth Partners — March 2026, definitive agreement to acquire this retina business for USD1.1 billion, doubling down on the retina/ophthalmology bet alongside RCA.
• Covetrus/MWI Animal Health merger-out — February 2026, Cencora agreed to merge Covetrus and MWI Animal Health (USD3.5 billion enterprise value); Cencora receives USD1.25 billion cash plus USD800 million preferred equity. This is how Cencora is monetizing and exiting its non-core animal health exposure.

The simple read: Cencora is selling animal health and buying more oncology and retina. Proceeds from the Covetrus/MWI deal help fund the specialty pivot.

Shariah Compliance Status

✅ Per Zoya screening, Cencora (COR) is classified as Shariah-Compliant. For Malaysian Muslim investors seeking US healthcare exposure, this is one of the larger names (mega-cap, ~USD59.6 billion market cap) that clears the basic screen.

One thing worth flagging: the debt-financed M&A spree (RCA, OneOncology) has materially raised the company's debt load. The compliant status holds under current screening methodology (typically revenue/interest-income based), but investors who apply their own stricter leverage overlay should keep an eye on this debt trend going forward.

This section is being refreshed with the latest figures. Please check back soon.

This section is being refreshed with the latest figures. Please check back soon.